Cosentyx

Cosentyx (secukinumab) is a recombinant humanized monoclonal antibody traded by VuRoyal (SuQian) Pharmaceutical Company LLC to injection grade, meeting ChP, USP, and EP standards; as a biologic, it has no traditional CAS number. It specifically targets interleukin-17A (IL-17A) to block its inflammatory pathway, and is used via subcutaneous injection to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and related immune-mediated conditions. It is distributed across North America, Central and South America, and Western and Eastern Europe.